The disposition of doxorubicin on repeated dosing

D. A. Rushing, S. C. Piscitelli, K. A. Rodvold, D. A. Tewksbury

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Twelve cancer patients (aged 49-74 years) receiving doxorubicin (66 ± 8 mg/m2) as a 1-hour intravenous infusion had serial serum samples (0-48 hours) obtained after the first and second courses of therapy. Mean number of days between courses was 24.3, and all patients had normal liver function. Patients received the same concomitant antineoplastic agents and doses in both courses. Doxorubicin and doxorubicinol concentrations were assayed by high-performance liquid chromatography and fitted to a two- or three- compartment infusion model. White blood cell and platelet toxicity were evaluated as (initial - nadir/initial)*100. Differences in pharmacokinetic parameters were determined by a paired t test. Wide intrapatient and interpatient variability was seen between therapeutic courses. A significant decrease in the apparent volume of distribution of the central compartment (V(c) = 16.6 versus 10.4 L/m2; P <.05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy. Doxorubicinol area under the curve and elimination half-life were similar between courses. Extensive chemotherapy-induced changes in white blood cell and platelet counts were observed but were similar in degree for courses 1 and 2. These data suggest that higher initial doxorubicin concentrations on the second course of therapy are secondary to an alteration in distribution volume (V(c)). In this subset of patients, however, these changes were not associated with an increase in hematologic toxicity.

Original languageEnglish (US)
Pages (from-to)698-702
Number of pages5
JournalJournal of Clinical Pharmacology
Volume33
Issue number8
StatePublished - 1993
Externally publishedYes

Fingerprint

Doxorubicin
Therapeutics
Platelet Count
Leukocyte Count
Intravenous Infusions
Antineoplastic Agents
Area Under Curve
Half-Life
Leukocytes
Blood Platelets
Pharmacokinetics
High Pressure Liquid Chromatography
Drug Therapy
Liver
Serum
Neoplasms
adriamycinol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Rushing, D. A., Piscitelli, S. C., Rodvold, K. A., & Tewksbury, D. A. (1993). The disposition of doxorubicin on repeated dosing. Journal of Clinical Pharmacology, 33(8), 698-702.

The disposition of doxorubicin on repeated dosing. / Rushing, D. A.; Piscitelli, S. C.; Rodvold, K. A.; Tewksbury, D. A.

In: Journal of Clinical Pharmacology, Vol. 33, No. 8, 1993, p. 698-702.

Research output: Contribution to journalArticle

Rushing, DA, Piscitelli, SC, Rodvold, KA & Tewksbury, DA 1993, 'The disposition of doxorubicin on repeated dosing', Journal of Clinical Pharmacology, vol. 33, no. 8, pp. 698-702.
Rushing DA, Piscitelli SC, Rodvold KA, Tewksbury DA. The disposition of doxorubicin on repeated dosing. Journal of Clinical Pharmacology. 1993;33(8):698-702.
Rushing, D. A. ; Piscitelli, S. C. ; Rodvold, K. A. ; Tewksbury, D. A. / The disposition of doxorubicin on repeated dosing. In: Journal of Clinical Pharmacology. 1993 ; Vol. 33, No. 8. pp. 698-702.
@article{06ba0a48278241b6a0ac47aadedb5d63,
title = "The disposition of doxorubicin on repeated dosing",
abstract = "Twelve cancer patients (aged 49-74 years) receiving doxorubicin (66 ± 8 mg/m2) as a 1-hour intravenous infusion had serial serum samples (0-48 hours) obtained after the first and second courses of therapy. Mean number of days between courses was 24.3, and all patients had normal liver function. Patients received the same concomitant antineoplastic agents and doses in both courses. Doxorubicin and doxorubicinol concentrations were assayed by high-performance liquid chromatography and fitted to a two- or three- compartment infusion model. White blood cell and platelet toxicity were evaluated as (initial - nadir/initial)*100. Differences in pharmacokinetic parameters were determined by a paired t test. Wide intrapatient and interpatient variability was seen between therapeutic courses. A significant decrease in the apparent volume of distribution of the central compartment (V(c) = 16.6 versus 10.4 L/m2; P <.05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy. Doxorubicinol area under the curve and elimination half-life were similar between courses. Extensive chemotherapy-induced changes in white blood cell and platelet counts were observed but were similar in degree for courses 1 and 2. These data suggest that higher initial doxorubicin concentrations on the second course of therapy are secondary to an alteration in distribution volume (V(c)). In this subset of patients, however, these changes were not associated with an increase in hematologic toxicity.",
author = "Rushing, {D. A.} and Piscitelli, {S. C.} and Rodvold, {K. A.} and Tewksbury, {D. A.}",
year = "1993",
language = "English (US)",
volume = "33",
pages = "698--702",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - The disposition of doxorubicin on repeated dosing

AU - Rushing, D. A.

AU - Piscitelli, S. C.

AU - Rodvold, K. A.

AU - Tewksbury, D. A.

PY - 1993

Y1 - 1993

N2 - Twelve cancer patients (aged 49-74 years) receiving doxorubicin (66 ± 8 mg/m2) as a 1-hour intravenous infusion had serial serum samples (0-48 hours) obtained after the first and second courses of therapy. Mean number of days between courses was 24.3, and all patients had normal liver function. Patients received the same concomitant antineoplastic agents and doses in both courses. Doxorubicin and doxorubicinol concentrations were assayed by high-performance liquid chromatography and fitted to a two- or three- compartment infusion model. White blood cell and platelet toxicity were evaluated as (initial - nadir/initial)*100. Differences in pharmacokinetic parameters were determined by a paired t test. Wide intrapatient and interpatient variability was seen between therapeutic courses. A significant decrease in the apparent volume of distribution of the central compartment (V(c) = 16.6 versus 10.4 L/m2; P <.05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy. Doxorubicinol area under the curve and elimination half-life were similar between courses. Extensive chemotherapy-induced changes in white blood cell and platelet counts were observed but were similar in degree for courses 1 and 2. These data suggest that higher initial doxorubicin concentrations on the second course of therapy are secondary to an alteration in distribution volume (V(c)). In this subset of patients, however, these changes were not associated with an increase in hematologic toxicity.

AB - Twelve cancer patients (aged 49-74 years) receiving doxorubicin (66 ± 8 mg/m2) as a 1-hour intravenous infusion had serial serum samples (0-48 hours) obtained after the first and second courses of therapy. Mean number of days between courses was 24.3, and all patients had normal liver function. Patients received the same concomitant antineoplastic agents and doses in both courses. Doxorubicin and doxorubicinol concentrations were assayed by high-performance liquid chromatography and fitted to a two- or three- compartment infusion model. White blood cell and platelet toxicity were evaluated as (initial - nadir/initial)*100. Differences in pharmacokinetic parameters were determined by a paired t test. Wide intrapatient and interpatient variability was seen between therapeutic courses. A significant decrease in the apparent volume of distribution of the central compartment (V(c) = 16.6 versus 10.4 L/m2; P <.05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy. Doxorubicinol area under the curve and elimination half-life were similar between courses. Extensive chemotherapy-induced changes in white blood cell and platelet counts were observed but were similar in degree for courses 1 and 2. These data suggest that higher initial doxorubicin concentrations on the second course of therapy are secondary to an alteration in distribution volume (V(c)). In this subset of patients, however, these changes were not associated with an increase in hematologic toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0027182890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027182890&partnerID=8YFLogxK

M3 - Article

C2 - 8408728

AN - SCOPUS:0027182890

VL - 33

SP - 698

EP - 702

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 8

ER -